Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

Micromet Inc. (Nasdaq: MITI)

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. MT103/MEDI-538, which is the first product candidate based on Micromet's novel BiTE® product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkins lymphoma.

The BiTE product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. Adecatumumab (MT201), a recombinant human monoclonal antibody which targets EpCAM expressing tumors, has completed two phase 2a clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. *

 

Period Start 2006-05-05 merged
  Group Amgen (Group)
  Today Amgen (Group)
  Predecessor CancerVax Corporation (Nasdaq: CNVX)
  Successor Amgen (Group)
Product Industry BIOTECH
Person Person Itin, Christian (Autolus 201603– CEO before Cytos 201211–201601 + Micromet 1999–2012 CEO + Co-founder + Zyomyx Inc)
     
Region Region Carlsbad, CA
  Country United States (USA)
  Street 6707 Democracy Boulevard, Suite 505
  City 20817 Bethesda, MD
  Tel +1-240-752-1420
    Address record changed: 2020-12-02
     
Basic data Employees C: 51 to 100 (2006-12-31)
  Currency USD
  Annual sales 21,041,000 (revenues, total, consolidated (2009) 2009-12-31)
  Profit -57,682,000 (2009-12-31)
  Cash 117,607,000 (2009-12-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2018-10-31

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Amgen (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px




» top